Literature DB >> 4765373

Clinical and pathologic study of canine lymphoma: clinical staging, cell classification, and therapy.

R A Squire, M Bush, E C Melby, L M Neeley, B Yarbrough.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4765373

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  7 in total

1.  Non-Hodgkin's lymphoma in children.

Authors:  D Pinkel; W Johnson; R J Aur
Journal:  Br J Cancer Suppl       Date:  1975-03

2.  The kinetics of methotrexate distribution in spontaneous canine lymphosarcoma.

Authors:  R J Lutz; R L Dedrick; J A Straw; M M Hart; P Klubes; D S Zaharko
Journal:  J Pharmacokinet Biopharm       Date:  1975-04

3.  Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.

Authors:  Cecile T Siedlecki; Philip H Kass; Martin J Jakubiak; Gillian Dank; Jarred Lyons; Michael S Kent
Journal:  Can Vet J       Date:  2006-01       Impact factor: 1.008

4.  The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer Institute Working Formulation.

Authors:  R F Carter; V E Valli; J H Lumsden
Journal:  Can J Vet Res       Date:  1986-04       Impact factor: 1.310

5.  Hemodynamic and biochemical alterations in dogs with lymphoma after induction of chemotherapy.

Authors:  D M Fine; K Selting; R C Backus; N F Rossi; M W Harmon; H E Durham; A W Spier
Journal:  J Vet Intern Med       Date:  2014-03-21       Impact factor: 3.333

Review 6.  Mechanisms of Drug Resistance in Veterinary Oncology- A Review with an Emphasis on Canine Lymphoma.

Authors:  Maurice Zandvliet; Erik Teske
Journal:  Vet Sci       Date:  2015-08-12

7.  Restored vision in a young dog following corticosteroid treatment of presumptive hypophysitis.

Authors:  Nina Marie Rzechorzek; Tiziana Liuti; Catherine Stalin; Katia Marioni-Henry
Journal:  BMC Vet Res       Date:  2017-02-28       Impact factor: 2.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.